# Cell-free DNA sequencing Sequencing of fragmentary cell-free DNA from blood — prenatal screening, minimal-residual-disease surveillance and therapy-selection liquid biopsy, pushed by error-corrected counting at ever-deeper limits of detection. The table carries two vendors with fully sourced dossier ledgers; the wider field awaits ledger-grade records. Source: https://en.bioecon.ru/technology/cell-free-dna-sequencing/ Updated: 2026-09-18 ## Overview and value chain Markers: [EC: EU IVDR 2017/746 companion-diagnostic framework + FDA/EMA oncology CDx pathways | OECD: Biotech & health | Regulator: FDA (USA), EMA (EU), NMPA (China)] Cell-free DNA sequencing reads the small fragments of DNA that dying cells shed into the bloodstream, turning a blood draw into a molecular sample of the tumors, the placenta or the transplant that shed them. The technology stacks three hard problems: recovering short (~140–170 bp) fragments at parts-per-thousand concentration against a vast wild-type background; building libraries from picogram inputs without letting preparation errors masquerade as variants; and suppressing sequencing noise with molecular barcodes and unique-molecule counting so that a signal hiding at one-in-a-million frequency survives the read. What began as prenatal trisomy screening has become three markets in one — non-invasive prenatal testing, minimal-residual-disease surveillance after treatment, and therapy-selection liquid biopsy — and each new market pushes the limit of detection another order of magnitude deeper. The regulatory record in the corpus shows how far that has gone: one vendor holds EU IVDR Class C certification across multiple cancers while another holds the first FDA approval for a liquid biopsy in non-small-cell lung cancer, and both run laboratory networks at clinical-throughput scale. Key directions of cell-free DNA sequencing: 1. **Minimal-residual-disease surveillance (MRD Monitoring):** tumor-informed and tumor-naive panels tracking recurrence months before imaging; Natera's Signatera holds EU IVDR Class C certification across multiple cancers plus FDA companion-diagnostic approval in muscle-invasive bladder cancer and a PMDA approval in Japan for colorectal cancer. 2. **Therapy-selection liquid biopsy (Therapy Selection):** comprehensive genomic profiling from plasma — Guardant Health's Guardant360 CDx has been FDA-approved since 2020, with a May 2026 approval for the Liquid CDx generation. 3. **Multi-cancer screening (Early Detection):** blood tests that look for signal before symptoms — Guardant's Shield test received FDA clearance in 2024 as the screening frontier of the cfDNA market. 4. **Prenatal and donor-derived sampling (NIPT and Beyond):** the original application — counting chromosome-scale aneuploidy from placental cfDNA — remains the volume base of the sequencing pipeline. ### Sectoral value chain ``` [blood draw] ──> [plasma separation] ──> [cfDNA extraction] │ (picogram library input) ▼ [clinical report] <── [variant calling/reporting] <── [error-corrected sequencing] ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Blood collection** | cfDNA-stabilizing tubes and logistics | **In:** patient blood. **Out:** plasma with preserved fragment landscape. | | **Plasma separation** | centrifugation within the stability window | **In:** whole blood. **Out:** cell-free plasma. | | **cfDNA extraction** | silica/magnetic purification of short fragments | **In:** plasma. **Out:** picogram-to-nanogram cfDNA. | | **Library preparation** | end repair, adapters, molecular barcodes | **In:** cfDNA. **Out:** sequencing-ready indexed libraries. | | **Error-corrected sequencing** | deep sequencing with unique-molecule counting | **In:** libraries. **Out:** variant calls at 0.01–0.1% allele frequency. | | **Reporting and CDx linkage** | clinical interpretation, therapy linkage | **In:** calls. **Out:** MRD, screening or therapy-selection reports. | Cross-cutting technologies of the sector: - **Molecular barcoding (UMI Error Correction):** unique molecular identifiers that let the pipeline separate true variants from sequencing noise. - **Tumor-informed panel design (Patient-Specific Panels):** bespoke assays built from each patient's tumor genotype for maximal MRD sensitivity. - **Companion-diagnostic regulatory chains (CDx Co-approvals):** drug–diagnostic co-approval packages that tie cfDNA assays to specific therapies. --- ## US The US is both the technology center and the reimbursement battleground — FDA approvals and Medicare coverage decisions set the pace for the whole field. ### First FDA liquid-biopsy approvals, MRD guideline traction, national lab networks - **Guardant360 approvals:** FDA approval of Guardant360 CDx in 2020 as the blood-based companion diagnostic for non-small-cell lung cancer, the Liquid CDx generation in May 2026, and the Shield screening test in 2024. - **Signatera's regulatory stack:** FDA companion-diagnostic approval in muscle-invasive bladder cancer, EU IVDR Class C certification across multiple cancers, and a PMDA approval in Japan — one assay carrying three regulatories. - **Clinical laboratory scale:** Natera's Austin expansion is designed to create the world's largest sequencing capacity and up to 400 new jobs, on top of laboratories in Austin, San Carlos and Boulder (Colorado). --- ## CN China runs a parallel cfDNA market at national scale, with NMPA pathways for prenatal screening and oncology panels and home-grown sequencing champions — the corpus's dossier coverage there is still ledger-thin, so this section carries market structure rather than vendor claims. ### NMPA oncology panels, prenatal screening volume, domestic sequencing platforms - **NMPA tumor-panel pathway:** Chinese liquid-biopsy panels clear the NMPA route separately from prenatal licenses, and oncology NGS leaders are submitting early-screening panels for colorectal cancer. - **Prenatal screening at population scale:** NIPT volume made China one of the largest cfDNA markets by draw count before oncology arrived. - **Domestic platforms:** Chinese sequencers supply the domestic cfDNA pipeline, decoupling it from US instrument exports. --- ## EU Europe's role is the IVDR: the 2017/746 regulation's Class C requirements are the strictest evidentiary bar the sector faces, and the certifications now appearing against it are the market passports. ### IVDR Class C certification, pharmacopoeial-era quality, PMDA-EU reciprocity - **Signatera under IVDR:** EU Class C certification across multiple cancer types — the first corpus-grounded example of an MRD assay clearing Europe's post-2022 device regime. - **Laboratory licensure map:** CLIA and CAP accreditation plus state licensure in New York and California shape US throughput, while European labs face national accreditation under the same ISO 15189 spine. - **Japan as reciprocal market:** PMDA approval for Signatera in colorectal cancer shows the MRD regulatory template already replicating beyond the US-EU axis. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Natera** | 🇺🇸 USA | *Signatera MRD, Panorama NIPT* | Tumor-informed MRD; IVDR Class C; FDA CDx; PMDA approval; $2.31 bn 2025 revenue | Commercial | | **Guardant Health** | 🇺🇸 USA | *Guardant360 CDx, Liquid CDx, Shield* | First FDA-approved liquid biopsy for NSCLC; CLIA/CAP labs; $982 m 2025 revenue | Commercial | --- ## Tech stack and innovations The stack is a noise war: every stage exists to keep preparation and sequencing errors from impersonating biology. 1. **Stabilized collection and extraction (Blood-to-Library Front End):** - cfDNA-stabilizing tubes hold the fragment landscape for days, protecting the ~140–170 bp tumor-derived fraction from dilution by genomic DNA. - case: high-throughput extraction feeding Natera's Austin expansion — designed to be the world's largest sequencing capacity. 2. **Molecular-barcoded libraries (UMI Counting):** - unique molecular identifiers tag each original fragment, so consensus collapsing can distinguish a one-in-a-million variant from a sequencing error. - case: tumor-informed Signatera panels tracking recurrence across multiple cancers under IVDR Class C certification. 3. **Multi-cancer and screening assays (Population-Scale cfDNA):** - screening moves the technology from patients to populations, demanding specificity at population scale. - case: Guardant's Shield blood test, FDA-cleared in 2024, with laboratory capacity investment accelerating through 2026 to match volume. --- ## Value chains and production pipelines ### Industrial pipeline of a cfDNA clinical laboratory (CLIA / CAP / IVDR regime) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Stabilized blood draw │ ───> │ 2. Plasma separation │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Error-corrected seq. │ <─── │ 3. Extraction + library │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Variant calling │ ───> │ 6. Clinical report, CDx │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Stabilized blood draw Blood is drawn into cfDNA-preserving tubes, fixing the fragment landscape against cell lysis during transport to the laboratory. #### Stage 2: Plasma separation Double centrifugation within the stability window separates plasma from cells, because a single lysed leukocyte can swamp a tumor's cfDNA signal. #### Stage 3: Extraction and library preparation Short-fragment-optimized purification recovers picogram cfDNA, and adapters with molecular barcodes convert it into pooled, indexed libraries. #### Stage 4: Error-corrected sequencing Deep sequencing runs with unique-molecule counting; consensus rules push the reliable detection threshold down to allele fractions ordinary panels cannot see. #### Stage 5: Variant calling Bioinformatics pipelines apply tumor-informed or tumor-naive models, converting counted molecules into recurrence, screening or therapy-selection calls. #### Stage 6: Clinical reporting Boarded interpretation links calls to therapy decisions under the CLIA/CAP/IVDR regime, closing the loop from blood draw to treatment choice.